Immune drug rituximab tested to shrink prostate tumors before surgery
Disease control
Completed
This early-phase trial tested whether rituximab, a drug that depletes B cells, could reduce immune cell infiltration in prostate tumors. Eight high-risk prostate cancer patients received four weekly doses before their scheduled prostate removal. The main goal was to see if B-cell…
Phase: EARLY_PHASE1 • Sponsor: Christopher Kane • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC